Ranolazine
- 2 independent labs in 2 countries
- 1 trial, 1 about aging
- Funders: National Natural Science Foundation of China and 6 more
- Animals1
- Cells1
- In silico1
Outcomes
5Mitochondrial damage
downin rats1
1 study
Mitochondrial damage
downin rats1
Ranolazine decreases mitochondrial damage in rats.
“alleviated mitochondrial structural damage in hippocampus and medial prefrontal cortex (mPFC).”
Animalsin ageing rats induced by D-galactosehippocampus and medial prefrontal cortex
European journal of pharmacologyJul 30, 2025
Cognitive function
upin rats1
1 study
Cognitive function
upin rats1
Ranolazine improves cognitive function in rats.
“In ageing rats, Ran not only enhanced spatial memory, exploratory behaviors and motor ability”
Animalsin ageing rats induced by D-galactose
European journal of pharmacologyJul 30, 2025
Physical function
upin worms1
1 study
Physical function
upin worms1
Ranolazine improves physical function in worms.
“improved the head swinging ability of ageing C. elegans”
Model organismsin ageing C. elegans
European journal of pharmacologyJul 30, 2025
Lifespan
upin worms1
1 study
Lifespan
upin worms1
Ranolazine extends lifespan in worms.
“The results revealed that Ran extended the lifespan of Caenorhabditis elegans (C. elegans)”
Model organisms
European journal of pharmacologyJul 30, 2025
Diastolic dysfunction
downin human cells1
1 study
Diastolic dysfunction
downin human cells1
Ranolazine decreases diastolic dysfunction in human cells.
“treatment with dasatinib and quercetin (D+Q) or with ranolazine (RAN) partially reversed the disease phenotype.”
Cellsin ET-1 and TGF-beta-induced DD heart-on-a-chip microtissues
Acta biomaterialiaJul 4, 2025
Trials
1 about aging, of 1About aging
Feasibility Trial for a Right Ventricular Failure Platform Trial
Phase 2Recruiting
Trial sponsors
1 trialPhase 230 people